{"id":"trigger-point-injection-with-bupivacaine","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site pain or bruising"},{"rate":null,"effect":"Temporary numbness at injection site"},{"rate":null,"effect":"Systemic toxicity (rare, with overdose)"}]},"_chembl":{"chemblId":"CHEMBL1098","moleculeType":"Small molecule","molecularWeight":"288.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bupivacaine is a local anesthetic that penetrates nerve cell membranes and reversibly binds to sodium channels from the inside, preventing depolarization and action potential propagation. When injected into myofascial trigger points (localized areas of muscle tension), it interrupts nociceptive signaling and provides localized pain relief. This allows muscle relaxation and can break the pain-spasm cycle associated with trigger point dysfunction.","oneSentence":"Bupivacaine blocks sodium channels in nerve fibers, interrupting pain signal transmission when injected directly into trigger points.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:14:33.239Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myofascial pain syndrome with trigger points"},{"name":"Musculoskeletal pain conditions"}]},"trialDetails":[{"nctId":"NCT04732507","phase":"PHASE2","title":"Investigating the Minimum Number of Needling Required to Optimize Trigger Point Injections Outcome","status":"ENROLLING_BY_INVITATION","sponsor":"University of Arizona","startDate":"2021-04-20","conditions":"Myofascial Pain, Myofascial Trigger Point Pain","enrollment":300},{"nctId":"NCT07322445","phase":"NA","title":"Multi-modal Imaging of Myofascial Pain - Phase 2","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-10-01","conditions":"Myofascial Pain","enrollment":100},{"nctId":"NCT03995641","phase":"PHASE4","title":"The Effect of Local Analgesia on Postoperative Gluteal Pain in Patients Undergoing Sacrospinous Ligament Fixation","status":"WITHDRAWN","sponsor":"Kettering Health Network","startDate":"2019-02-02","conditions":"Postoperative Pain, Pelvic Organ Prolapse, Trigger Point Injection","enrollment":""},{"nctId":"NCT05792111","phase":"PHASE4","title":"Caudal Epidural Steroid and Trigger Point Injection","status":"UNKNOWN","sponsor":"Abant Izzet Baysal University","startDate":"2022-10-12","conditions":"Myofascial Trigger Point Pain","enrollment":72},{"nctId":"NCT04640896","phase":"PHASE4","title":"Trigger Point Injections in Anterior Cervical Surgery","status":"RECRUITING","sponsor":"George Washington University","startDate":"2020-11-05","conditions":"Myofacial Pain, Pain, Neck, Pain, Back","enrollment":60},{"nctId":"NCT04704297","phase":"PHASE4","title":"Trigger Point Injection for Myofascial Pain Syndrome in the Low Back: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"Madigan Army Medical Center","startDate":"2020-12-28","conditions":"Low Back Pain, Myofascial Pain Syndrome Lower Back","enrollment":180},{"nctId":"NCT01906944","phase":"PHASE2","title":"Ultrasound Guided Transversus Abdominis Plane (TAP) vs. Trigger Point Injection (TPI) for Abdominal Wall Pain","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2012-01","conditions":"Abdominal Pain","enrollment":62},{"nctId":"NCT01845532","phase":"NA","title":"Analgesic Effect of Trigger Point Injection and EMLA for Shoulder Pain in Laparoscopic Hysterectomy","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2013-04","conditions":"Myoma of Uterus","enrollment":75},{"nctId":"NCT02022722","phase":"PHASE4","title":"Trigger Point Injections and Pelvic Rehabilitation for the Treatment of Pelvic Floor Myalgia and Sexual Pain","status":"UNKNOWN","sponsor":"University of Cincinnati","startDate":"2013-08","conditions":"Dyspareunia","enrollment":36},{"nctId":"NCT00635037","phase":"NA","title":"Myofascial Pain:Acupuncture Versus Trigger Point Injection Combined With Dipyrone and Cyclobenzaprine","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2004-06","conditions":"Myofascial Pain Syndromes","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Trigger point injection with bupivacaine","genericName":"Trigger point injection with bupivacaine","companyName":"George Washington University","companyId":"george-washington-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bupivacaine blocks sodium channels in nerve fibers, interrupting pain signal transmission when injected directly into trigger points. Used for Myofascial pain syndrome with trigger points, Musculoskeletal pain conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}